Baird downgraded Oscar Health (OSCR) to Neutral from Outperform with a price target of $14, down from $28. The firm cites its caution on the healthcare exchange end market for the downgrade. Given Oscar’s recent pre-announced Q2 and 2025 outlook revision, Baird is increasingly cautious into 2026 and beyond. There is now significant complexity in projecting Oscar’s risk adjustment revenue, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health downgraded to Neutral from Outperform at Baird
- Moderately bullish activity in Oscar Health with shares up 1.8%
- Largest borrow rate increases among liquid names
- Oscar Health Faces Financial Instability Amid Pricing Challenges and Revised Earnings Expectations
- Oscar Health price target lowered to $11 from $17 at Barclays